SELLAS Life Sciences Group Financial Ratios
NASDAQ: SLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
11.65+0.39 (+3.46%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
SELLAS Life Sciences Group ratio analysis
Return on equity reached -37.9%, meaning SELLAS Life Sciences Group generated -0.38 dollars of profit for every dollar of shareholders' equity. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
SELLAS Life Sciences Group financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price / sales | — | — | — | 45.77 | 11.26 | 24.39 | — | — | — | — |
| Price / book | 6.69 | 6.98 | — | 9.44 | 4.21 | 1.66 | 1.64 | 3.49 | 440.94 | — |
| Gross margin | — | — | — | 90.0% | 97.4% | 100.0% | — | — | — | — |
| Operating margin | — | — | — | -4,195.0% | -332.8% | -893.8% | — | — | — | — |
| Net margin | — | — | — | -4,130.1% | -272.4% | -881.9% | — | — | — | — |
| Free cash flow margin | — | — | — | -2,380.9% | -342.4% | -548.3% | — | — | — | — |
| Return on equity (ROE) | -37.9% | -326.3% | — | -851.4% | -101.7% | -59.9% | -316.6% | -527.6% | -1,147.5% | — |
| Return on assets (ROA) | -34.3% | -158.9% | -600.4% | -197.2% | -78.8% | -36.4% | -116.2% | -163.6% | -70.9% | -275.4% |
| Debt / equity | — | — | — | — | — | — | — | 0.00 | 5.31 | — |
| Current ratio | 10.72 | 1.72 | 0.23 | 1.14 | 4.63 | 2.99 | 1.56 | 0.98 | 0.53 | 1.11 |
| Revenue growth | — | — | -100.0% | -86.8% | 300.0% | — | — | — | — | — |